抄録 Various N-[3, 5-bis (trifluoromethyl) benzyl]-N-methylcarbamoyl heterocycles (1, 2 and
3) modified at rings A and B in the isoquinolone (1a) and pyrido [3, 4-b] pyridine (2a) nuclei …

Experiments were performed to characterize the pharmacology of SCH 206272 [(R, R)-1′[5-
[(3, 5-dichlorobenzoyl) methylamino]-3-(3, 4-dichlorophenyl)-4 (Z)-(methoxyimino) pentyl]-N …

Experiments were conducted to characterize the metabolism of ezlopitant alkene (CJ-
12,458), an active metabolite of ezlopitant, in human liver microsomes. In incubations with …

Two asymmetric syntheses of the NK1 receptor antagonist 1-[2-(R)-{1-(R)-[3, 5-bis
(trifluoromethyl) phenyl] ethoxy}-3-(R)-(3, 4-difluorophenyl)-4-(R)-tetrahydro-2 H-pyran-4 …

NKP608 is a potent, selective and orally active non-peptidic neurokinin-1 (NK1)-receptor
antagonist for which anxiolytic-and antidepressant-like effects have been described in …

A number of extensive reviews have been published which cover much of the current
literature on receptor distribution, in vitro and in vivo pharmacology, potential clinical utilities …

A new and highly potent NK1 antagonist,(aR, 9R)-3 [(aR, 9R)-7-[3, 5-bis (trifluoromethyl)
benzyl]-8, 9, 10, 11-tetrahydro-9-methyl-5-(4-methylphenyl)-7H-[1, 4] diazocino [2, 1-g][1, 7] …

The concise synthesis of a stereochemically rich hNK-1 receptor antagonist is described.
The synthesis is highlighted by an SN2 reaction of an enantiomerically pure α-alkoxy …

The competitive area of neurokinin (NK) receptor antagonists has recently seen the
publication of early clinical results which provide strong support for their use in the treatment …

The involvement of tachykinin neuropeptides, such as substance P and the neurokinins, in
pain transmission is supported by a wealth of evidence. At present. the therapeutic potential …